Global Lung Cancer Genomic Testing Market 2023-2029

March 2023 | 71 pages | ID: G972DA75A6E0EN
Gen Consulting Company

Abstracts

Lung cancer genomic testing is a type of genetic testing that screens tumors for changes or mutations in their DNA. It helps to identify specific genomic alterations in tumor cells, which can be useful for identifying targeted treatments that may be more effective than chemotherapy or radiation. The process of lung cancer genomic testing usually involves taking a small sample of tumor tissue, which is then analyzed through various techniques like next-generation sequencing (NGS) or polymerase chain reaction (PCR). These techniques help to identify genetic mutations or alterations in the tumor DNA that may be driving cancer growth. According to latest analysis, the global lung cancer genomic testing market was USD 1,515.0 million in 2022 and is expected to reach USD 2,762.4 million in 2029 and register a CAGR of 8.96% during the forecast period, 2023-2029.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global lung cancer genomic testing market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the type, sample type, panel type, technology, end user, and region. The global market for lung cancer genomic testing can be segmented by type: services, products. The services segment held the largest revenue share in 2022. Lung cancer genomic testing market is further segmented by sample type: tissue biopsy, liquid biopsy. Among these, the tissue biopsy segment was accounted for the highest revenue generator in 2022. Based on panel type, the lung cancer genomic testing market is segmented into: multi-gene panel, single-gene panel. The multi-gene panel segment captured the largest share of the market in 2022. On the basis of technology, the lung cancer genomic testing market also can be divided into: polymerase chain reaction (PCR), next-generation sequencing, fish/in-situ hybridization (ISH), others. According to the research, the polymerase chain reaction (PCR) segment had the largest share in the global lung cancer genomic testing market. Lung cancer genomic testing market by end user is categorized into: research organization, hospitals/clinics, diagnostic laboratories, others. The lung cancer genomic testing market by region can be segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America.

Market Segmentation
By type: services, products
By sample type: tissue biopsy, liquid biopsy
By panel type: multi-gene panel, single-gene panel
By technology: polymerase chain reaction (PCR), next-generation sequencing, fish/in-situ hybridization (ISH), others
By end user: research organization, hospitals/clinics, diagnostic laboratories, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report has also analysed the competitive landscape of the global lung cancer genomic testing market with some of the key players being Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Illumina, Inc., Abbott Laboratories, Qiagen N.V., Centogene N.V., Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Inc., Quest Diagnostics Incorporated, OPKO Health, Inc., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report
To analyze and forecast the market size of the global lung cancer genomic testing market.
To classify and forecast the global lung cancer genomic testing market based on type, sample type, panel type, technology, end user, region.
To identify drivers and challenges for the global lung cancer genomic testing market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global lung cancer genomic testing market.
To identify and analyze the profile of leading players operating in the global lung cancer genomic testing market.

Why Choose This Report
Gain a reliable outlook of the global lung cancer genomic testing market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY TYPE

Services
Products

PART 6. MARKET BREAKDOWN BY SAMPLE TYPE

Tissue biopsy
Liquid biopsy

PART 7. MARKET BREAKDOWN BY PANEL TYPE

Multi-gene panel
Single-gene panel

PART 8. MARKET BREAKDOWN BY TECHNOLOGY

Polymerase chain reaction (PCR)
Next-generation sequencing
Fish/in-situ hybridization (ISH)
Others

PART 9. MARKET BREAKDOWN BY END USER

Research organization
Hospitals/clinics
Diagnostic laboratories
Others

PART 10. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 11. KEY COMPANIES

Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
Agilent Technologies, Inc.
Illumina, Inc.
Abbott Laboratories
Qiagen N.V.
Centogene N.V.
Bio-Rad Laboratories, Inc.
Laboratory Corporation of America Holdings
NeoGenomics Laboratories, Inc.
Quest Diagnostics Incorporated
OPKO Health, Inc.

DISCLAIMER